文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

基于CT的在线自适应放疗改善前列腺癌立体定向体部放疗的靶区覆盖与危及器官保护

CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-10-24

该回顾性研究纳入7例接受5次前列腺自适应立体定向体部放疗的患者,利用AI辅助的CT在线自适应系统每日调整计划并比较自适应计划与初始计划的剂量差异。结果显示自适应计划显著提高各靶区PTV的V100并降低直肠D0.03cc剂量,膀胱剂量轻度增加但满足约束,未发生≥3级急性胃肠道/泌尿生殖道不良事件。

要点

  • 每日自适应计划使PTV 4000、PTV 3625和PTV 2500的V100分别平均提高21.4%±4.3%、8.7%±1.1%和11.5%±3.1%。
  • 自适应计划每分次直肠D0.03cc平均降低38.8 cGy±5.95 cGy(5次共194 cGy)。
  • 自适应计划膀胱剂量每分次轻度增加10.9 cGy±4.93 cGy,但各分次均满足膀胱约束。

核心结论

  • 基于CT的在线自适应立体定向体部放疗在前列腺癌中实现了PTV覆盖和直肠D0.03cc剂量的统计学显著且具有临床意义的改善。
  • 评估CT自适应全盆腔前列腺立体定向体部放疗的试验正在进行中。

研究设计与样本

  • 回顾性分析7例 favorable intermediate to oligometastatic 前列腺癌患者,接受5分次前列腺自适应立体定向体部放疗。
  • 处方剂量为前列腺和精囊3625 cGy,6例另接受盆腔淋巴结2500 cGy,5例接受前列腺推量至4000 cGy。
  • 每分次获取CBCT,使用AI分割/变形危及器官(直肠、膀胱、肠、乙状结肠、股骨),手动调整体积并添加PTV外扩,生成自适应计划并与初始计划比较每分次剂量。

主要发现

  • 7例患者完成35分次自适应放疗。
  • 自适应计划使所有靶区PTV V100平均提高:PTV 4000为21.4%±4.3%(p<0.0001),PTV 3625为8.7%±1.1%(p<0.0001),PTV 2500为11.5%±3.1%(p=0.0013)。
  • 与初始计划相比,自适应计划每分次直肠D0.03平均降低38.8 cGy±5.95 cGy(p<0.0001),5分次共194 cGy。
  • 自适应计划每分次膀胱剂量轻度增加10.9 cGy±4.93 cGy(p=0.0424),但各分次均满足膀胱约束。
  • 自适应计划与初始计划之间乙状结肠或肠剂量无统计学显著差异。

关键数值与推荐

  • V100和D0.03 cc在计划与自适应计划间采用Student t检验比较,显著性阈值P<0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Stereotactic body radiation therapy (SBRT) is an emerging treatment modality for clinically localized prostate cancer (PCa). Online daily adaptive radiotherapy (ART) could potentially improve the therapeutic ratio of prostate SBRT by accounting for inter-fraction variation in target and OAR volumes. To our knowledge, no group has evaluated the clinical utility of a novel AI-augmented CT-based ART system for prostate SBRT. In this study we hypothesized that adaptive prostate SBRT plans would result in improved target coverage and lower dose to OARs in comparison to unadapted treatment plans. METHODS: Seven patients with favorable intermediate to oligometastatic PCa treated with 5-fx prostate adaptive SBRT were retrospectively reviewed. Patients were treated with 3625 cGy to the prostate and seminal vesicles. 6 patients additionally received 2500 cGy to the pelvic nodes, 5 patients underwent a boost to 4000 cGy to the prostate. For each fraction, a CBCT was acquired and OARs (rectum, bladder, bowel, sigmoid, femurs) were segmented/deformed using AI. CTVs were rigidly registered. Volumes were adjusted manually and PTV expansions added. Adaptive treatment plans were developed based on the contoured targets and OARs and dose to these volumes for the adapted vs. initial plans were compared for each fraction. V100 and the D0.03 cc between scheduled and adapted treatment plans were compared using a Student's t-test, with significance threshold of P < 0.05. RESULTS: Seven patients completed 35 Fx's of adaptive RT. Daily adaptation resulted in a statistically significant mean improvement in PTV V100 for all targets: [21.4 % ± 4.3 % for PTV 4000 (p < 0.0001); 8.7 % ± 1.1 % for PTV 3625 (p < 0.0001); and 11.5 % ± 3.1 % for PTV 2500 (p = 0.0013)]. Mean rectal D0.03 was significantly reduced by 38.8 cGy ± 5.95 cGy (p < 0.0001) per fraction (194 cGy/5 fractions) compared to the initial plans. There was a modest increase in bladder dose of 10.9 cGy ± 4.93 cGy per fraction (p = 0.0424) for the adaptive plans. The adaptive plans met bladder constraints for every fraction. There were no statistically significant differences between sigmoid or bowel dose for adapted vs. initial plans. No patients experienced acute CTCAE grade ≥ 3 GI/GU adverse events (median F/U 9.5 months). All statistically significant differences were maintained in the presence and absence of rectal hydrogel spacer (p < 0.05). CONCLUSIONS: CT-based online adaptive SBRT resulted in statistically significant and clinically meaningful improvements in PTV coverage and D0.03 cc dose to the rectum. A trial evaluating CT adaptive whole-pelvis prostate SBRT is underway.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Waters M, Price A, Laugeman E, et al. CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer. Clin Transl Radiat Oncol. 2023. PMID: 38021093. doi:10.1016/j.ctro.2023.100693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。